Assertio Therapeutics market cap is $72.1 m, and annual revenue was $229.50 m in FY 2019

Assertio Therapeutics Net income (Q1, 2020)41.2 M

Assertio Therapeutics EBIT (Q1, 2020)-16.6 M

Assertio Therapeutics Cash, 31-Mar-2020106 M

Assertio Therapeutics EV-33.5 M

Assertio Therapeutics revenue was $229.50 m in FY, 2019

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 70.7m | (29.8m) | 43.3m | 131.8m | (75.7m) | (88.7m) | (102.5m) | 36.9m | (217.2m) |

## Depreciation and Amortization | 420.0k | 2.6m | 6.2m | 12.0m | 85.7m | 109.4m | 105.5m | 106.4m | 104.1m |

## Accounts Receivable | (6.2m) | 807.0k | (7.8m) | (15.5m) | (44.1m) | (30.9m) | 30.1m | 35.3m | (5.5m) |

## Inventories | (3.8m) | (2.3m) | 4.3m | 1.7m | 9.3m | (3.7m) | (1.9m) | 9.0m | (316.0k) |

## Accounts Payable | 7.8m | 5.7m | |||||||

## Cash From Operating Activities | 57.7m | (31.0m) | 9.8m | (55.9m) | 143.9m | 65.5m | 62.2m | 72.5m | 90.5m |

## Purchases of PP&E | (698.0k) | (6.9m) | (1.8m) | (599.0k) | (1.7m) | (2.9m) | (666.0k) | (5.5m) | (1.5m) |

## Cash From Investing Activities | (62.2m) | 33.3m | (38.0m) | (47.3m) | (1.1b) | 45.5m | 57.9m | (7.1m) | (1.5m) |

## Long-term Borrowings | (2.2m) | (120.0m) | |||||||

## Cash From Financing Activities | 6.1m | 2.7m | 243.9m | 347.2m | 576.6m | (94.4m) | (110.9m) | (81.3m) | (157.8m) |

## Net Change in Cash | 1.5m | 5.0m | 215.6m | 244.0m | (387.6m) | 16.6m | 9.2m | (15.9m) | (68.8m) |

## Interest Paid | 133.0k | 39.5m | 71.1m | 55.5m | 48.4m | 37.8m | |||

## Income Taxes Paid | (421.0k) | (91.0k) | 45.0k | 58.3m | (4.0m) | (14.4m) | 121.0k | 6.5m | 4.4m |

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.4 x |